German Merck considering generics sale

Share this article:
German chemicals company Merck KGaA is considering shedding its generics business, which could fetch 4 billion euros ($5.2 billion). Merck has hired Bear Stearns to vet potential bidders. The generics business had sales of 1.8 billion euros ($2.3 billion) in 2005. Merck is buying Swiss biotech Serono for $13.3 billion, after failing to buy the rival Schering last year, and may be under pressure to cut debt. Among those expected to express interest in the unit are Teva and Novartis, as are private equity firms including Blackstone and KKR. Iceland’s Actavis and KKR and Blackstone lost a bidding battle against Barr Pharmaceuticals, which bought Croatian drugmaker Pliva for $2.5 billion last year. Also last year, Novartis bought generics company Hexal for $8 billion.
Share this article:

Email Newsletters

More in News

FDA kind of OKs Lilly/BI's Lantus look-alike

FDA kind of OKs Lilly/BI's Lantus look-alike

Sanofi's patent lawsuit triggered the tentative approval of the Lilly-BI Lantus competitor.

GSK relaunches COPD.com

GSK relaunches COPD.com

The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.

Six things for pharma marketers to know: Tuesday, August 19

Six things for pharma marketers to know: Tuesday, ...

Lilly/BI receives tentative approval for insulin biosimilar; Ebola death rate hits new high; LaMattina sounds off on Pfizer's oncology efforts; art therapy becoming the norm in hospitals.